Mezlocillin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Mezlocillin is a broad-spectrum penicillin antibiotic. It is active against both Gram-negative and some Gram-positive bacteria. Unlike most other extended spectrum penicillins, it is excreted by the liver, therefore it is useful for biliary tract infections, such as ascending colangitis.

Like all other beta-lactam antibiotics, mezlocillin inhibits the third and last stage of bacterial cell wall synthesis by binding to penicillin binding proteins. This ultimately leads to cell lysis.

• Bacteroides spp., including B. fragilis
• Enterobacter spp.
• Escherichia coli
• Haemophilus influenzae
• Klebsiella species
• Morganella morganii
• Neisseria gonorrhoeae
• Proteus mirabilis
• Proteus vulgaris
• Pseudomonas spp., including P. aeruginosa
• Serratia marcescens

• Enterococcus faecalis
• Peptostreptococcus spp.

• Template:DiseasesDB
• Template:GPnotebook
• Duke
• Kristof R, Clusmann H, Koehler W, Fink K, Schramm J (1998). “Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange”. J Neurol Neurosurg Psychiatry. 64 (3): 379–81. doi:10.1136/jnnp.64.3.379. PMC 2170014. PMID 9527154.CS1 maint: Multiple names: authors list (link)
• McCormick P, Greenslade L, Kibbler C, Chin J, Burroughs A, McIntyre N (1997). “A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients”. Hepatology. 25 (4): 833–6. doi:10.1002/hep.510250408. PMID 9096584.CS1 maint: Multiple names: authors list (link)
• Rohde B, Werner U, Hickstein H, Ehmcke H, Drewelow B (1997). “Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure”. Eur J Clin Pharmacol. 53 (2): 111–5. doi:10.1007/s002280050347. PMID 9403281.CS1 maint: Multiple names: authors list (link)